[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE439845T1 - Kombination von einem ístrogen und einem androgen zur behandlung von hormonmangel in der ístrogenersatztherapie für frauen - Google Patents

Kombination von einem ístrogen und einem androgen zur behandlung von hormonmangel in der ístrogenersatztherapie für frauen

Info

Publication number
ATE439845T1
ATE439845T1 AT01989306T AT01989306T ATE439845T1 AT E439845 T1 ATE439845 T1 AT E439845T1 AT 01989306 T AT01989306 T AT 01989306T AT 01989306 T AT01989306 T AT 01989306T AT E439845 T1 ATE439845 T1 AT E439845T1
Authority
AT
Austria
Prior art keywords
estrogen
women
replacement therapy
androgen
treatment
Prior art date
Application number
AT01989306T
Other languages
English (en)
Inventor
Thomas Leonard
R Waldon
Original Assignee
Barr Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Barr Lab Inc filed Critical Barr Lab Inc
Application granted granted Critical
Publication of ATE439845T1 publication Critical patent/ATE439845T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
AT01989306T 2000-12-22 2001-12-21 Kombination von einem ístrogen und einem androgen zur behandlung von hormonmangel in der ístrogenersatztherapie für frauen ATE439845T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25814200P 2000-12-22 2000-12-22
PCT/US2001/051045 WO2002058706A2 (en) 2000-12-22 2001-12-21 Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy

Publications (1)

Publication Number Publication Date
ATE439845T1 true ATE439845T1 (de) 2009-09-15

Family

ID=22979245

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01989306T ATE439845T1 (de) 2000-12-22 2001-12-21 Kombination von einem ístrogen und einem androgen zur behandlung von hormonmangel in der ístrogenersatztherapie für frauen

Country Status (11)

Country Link
US (3) US20020151530A1 (de)
EP (2) EP1343509B1 (de)
JP (2) JP4768955B2 (de)
KR (1) KR100849919B1 (de)
AT (1) ATE439845T1 (de)
AU (1) AU2002243411B2 (de)
CA (1) CA2431645C (de)
DE (1) DE60139634D1 (de)
ES (1) ES2389639T3 (de)
MX (1) MXPA03005742A (de)
WO (1) WO2002058706A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002338277B2 (en) * 2001-03-16 2007-11-22 Wyeth Estrogen replacement therapy
WO2003041719A1 (en) * 2001-11-15 2003-05-22 Pantarhei Bioscience B.V. Method of contraception in mammalian females and pharmaceutical kit for use in such method
WO2005021056A1 (en) * 2003-08-21 2005-03-10 Cns, Inc. Effervescent delivery system
EP2803357B1 (de) 2004-06-25 2020-11-18 The Johns-Hopkins University Angiogenesehemmer
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
EP1853272A1 (de) * 2005-02-03 2007-11-14 Duramed Pharmaceuticals, Inc. Zusammensetzungen aus unkonjugierten östrogenen und anwendungsverfahren dafür
CA2635575A1 (en) * 2005-12-27 2007-07-05 Duramed Pharmaceuticals, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
WO2010075175A1 (en) * 2008-12-23 2010-07-01 Quest Diagnostics Investments Incorporated Mass spectrometry assay for estrogenic compounds
EP3936133A1 (de) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natürliche kombinationshormonersatzformulierungen und therapien
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4154820A (en) * 1976-02-23 1979-05-15 Akzona Incorporated Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
US4826831A (en) 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
US5043331A (en) 1989-06-15 1991-08-27 Orion-Yhtyma Oy Treatment of postmenopausal disorders
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5688765A (en) * 1992-04-21 1997-11-18 The Schepens Eye Research Institute, Inc. Ocular therapy in Sjogren's syndrome using topically applied androgensor TGF-β
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
JPH10279483A (ja) * 1997-02-04 1998-10-20 Kaken Pharmaceut Co Ltd 骨密度増加剤
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
WO2000074684A1 (en) * 1999-06-04 2000-12-14 The General Hospital Corporation Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use
EP1189619A4 (de) * 1999-06-11 2004-06-09 Watson Pharmaceuticals Inc Verabreichung von nicht-oralen androgenen steroiden an die frau

Also Published As

Publication number Publication date
JP2010077149A (ja) 2010-04-08
DE60139634D1 (de) 2009-10-01
MXPA03005742A (es) 2003-09-05
EP2116250B1 (de) 2012-06-20
US20020151530A1 (en) 2002-10-17
EP1343509A2 (de) 2003-09-17
JP2004520375A (ja) 2004-07-08
WO2002058706A3 (en) 2003-03-13
KR100849919B1 (ko) 2008-08-04
ES2389639T3 (es) 2012-10-30
AU2002243411B2 (en) 2007-02-08
US20060154907A1 (en) 2006-07-13
US20030195177A1 (en) 2003-10-16
WO2002058706A2 (en) 2002-08-01
CA2431645A1 (en) 2002-08-01
KR20030068187A (ko) 2003-08-19
EP1343509B1 (de) 2009-08-19
EP2116250A1 (de) 2009-11-11
CA2431645C (en) 2010-04-27
JP4768955B2 (ja) 2011-09-07

Similar Documents

Publication Publication Date Title
ATE439845T1 (de) Kombination von einem ístrogen und einem androgen zur behandlung von hormonmangel in der ístrogenersatztherapie für frauen
DE69432990D1 (de) PROGESTAGEN-FREIE FORMULIERUNGEN VON GnRH UND ESTROGEN ZUR BEHANDLUNG VON BENIGNEN GYNÄKOLOGISCHEN STÖRUNGEN
DE69731302D1 (de) Verwendung von substanzen, die die östrogen wirkung fördern, zur behandlung von wunden
EA200300283A1 (ru) Селективные модуляторы андрогенового рецептора и способы их применения
DE60141587D1 (de) Verfahren zur behandlung von erektionsstörungen und steigerung der libido bei männern
DE60324431D1 (de) Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata- oder gebahrmutterkrebs
DE60228583D1 (de) Verfahren und materialien für die behandlung des testosteron-mangels bei männern
ATE212841T1 (de) Yohimbine und arginin enthaltende zusammensetzung zur behandlung der erektilen fehlfunktion
CH1272195H1 (de)
DE60330888D1 (de) Verwendung von drospirenon zur behandlung von hypertension
ATE270554T1 (de) Kombination der progesteron und mifepristone für krebs-therapie
DE69932922D1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen
DE60334830D1 (de) Furin-hemmer zur behandlung von fibrose und narbenbildung
DE59904042D1 (de) Medikament zur prophylaxe und/oder behandlung des mammarkarzinoms enthaltend einen steroidalen aromataseinhibitor
ATE506986T1 (de) Substanzen und mittel zur positiven beeinflussung von kollagen
DE69900774D1 (de) Verwendung von topische präparationen mit glyceryl trinitrat und lanolin zur behandlung von erektilen funktionsstörungen
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
ATE251460T1 (de) Verwendung von danazol zur behandlung von hypogonadismus in männern
DE59807874D1 (de) Budesonid zur behandlung von cholestatischen lebererkrankungen
NO20014180L (no) Anvendelse av fluorinerte triazoler til behandling av smerte og smertefulle lidelser eller oppmerksomhetshunger

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties